论文部分内容阅读
对１１例癌性胸膜炎患者，采用新的蒽环类抗癌药物──吡柔比星（ＴＨＰ）４０ｍｇ／ｂｏｄｙ作胸腔灌注治疗。所有病例均只进行了一个疗程，１１例的疗效和副作用皆可评价，总有效率为８１．８％，６例ＣＲ。３例ＰＲ，２例无效。副作用主要是：发热（７３％），胸痛（３６．４％，）食欲不振（１８．２％），恶心（１８．２％），骨髓抑制９％，无１例脱发。所有副作用患者皆可耐受，而且在停药后逐渐消失，本研究表明ＴＨＰ胸腔内灌注疗法，对癌性胸膜炎是一种无严重副作用，可行的治疗方法。
In 11 patients with cancerous pleurisy, a new anthracycline anti-cancer drug, THP 40 mg/body, was used for perfusion. Only one course of treatment was performed in all cases. Efficacy and side effects were evaluated in 11 patients. The total effective rate was 81.8% and 6 cases were CR. In 3 cases of PR, 2 cases were invalid. The main side effects were: fever (73%), chest pain (36.4%), loss of appetite (18.2%), nausea (18.2%), myelosuppression (9%), and no hair loss. All patients with side effects were tolerated and gradually disappeared after discontinuation. This study shows that THP intrathoracic infusion therapy is a viable treatment for cancerous pleurisy without severe side effects.